$255 million deal expands Zoetis companion animal product portfolio to bring veterinarians solutions for pain, diabetes and oncology. Transaction furthers Zoetis’ bolt-on acquisition strategy aimed at expanding complementary animal health businesses to create additional value for shareholders.
The deal was announced in today, just one day ahead of the Zoetis Inaugural Investor Day on Tuesday, 18 November. Zoetis has received a great deal of attention, since activist investor William Ackman purchased holdings in the company. Just last week Zoetis adopted a Shareholders Rights Plan which has been referred to as a 'poison pill' intended to protect existing shareholders.
See More
No comments:
Post a Comment